Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Grzegorz S Nowakowski

ECOG-ACRIN Cancer Research Group

Intervention

Cyclophosphamide(drug)

Enrollment

349 target

Eligibility

18 years · All sexes

Timeline

2013 – 2026

Study locations (30)

• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Mayo Clinic in Arizona, Scottsdale, Arizona, United States
• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States
• Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
• Sutter Auburn Faith Hospital, Auburn, California, United States
• Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
• Kaiser Permanente-Bellflower, Bellflower, California, United States
• Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
• Kaiser Permanente South Bay, Harbor City, California, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07538180
  Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
  Sun Yat-sen University
• RECRUITINGNCT07070648
  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT06829771
  Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• RECRUITINGPHASE3NCT06717347
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT06687772
  CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
  Washington University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06760039
  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
  Sun Yat-sen University
• RECRUITINGPHASE2NCT06701357
  CR-CHOP+X in Previously Untreated DEL
  Ruijin Hospital
• RECRUITINGPHASE2NCT06664411
  Pola-ZR2P in Previously Untreated DLBCL
  Navy General Hospital, Beijing

See all trials for Diffuse large B-cell lymphoma with chronic inflammation →